Yüklüyor......
The diffuse large B-cell lymphoma – where do we stand now in everyday clinical practice
BACKGROUND: Due to superior results observed with the addition of rituximab into treatment of patients with the diffuse large B-cell lymphoma (DLBCL),the R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) regimen and its variants became the standard initial treatment of...
Kaydedildi:
| Asıl Yazarlar: | , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Versita, Warsaw
2012
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3472942/ https://ncbi.nlm.nih.gov/pubmed/23077452 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2478/v10019-012-0002-6 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|